Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12254-12264

  Hou, Jun ^a   van Oord, Gertine ^a   Groothuismink, Zwier M A ^a   Claassen, Mark A A ^a   Kreefft, Kim ^a   Zaaraoui Boutahar, Fatiha ^a   van IJcken, Wilfred F J ^a   Osterhaus, Albert D M E ^a   Janssen, Harry L A ^a,b   Andeweg, Arno C ^a   de Knegt, Robert J ^a   Boonstra, Andre ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 16; INTERLEUKIN 32; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RIBAVIRIN; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIPARTITE MOTIF PROTEIN 5; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ACCURACY; ADULT; APOPTOSIS; ARTICLE; AUTOPHAGY; BACTERIAL GENE; BLOOD SAMPLING; CCND3 GENE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL10 GENE; DDX60 GENE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HEPATITIS C; HUMAN; HUMAN CELL; IFI6 GENE; IL16 GENE; IL32 GENE; MALE; NONHUMAN; NUCLEIC ACID METABOLISM; NUCLEOTIDE SEQUENCE; OAS1 GENE; PROTEIN METABOLISM; RASSF1 GENE; RECURRENT DISEASE; STAT1 GENE; TRIM5 GENE; VIRAL CLEARANCE; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84907963596     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00775-14     Document Type: Article

References (32)

1. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46. http://dx.doi.org/10.1053/jhep.2002.36806.
2. Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52. http://dx.doi.org/10.1056/NEJM200107053450107.
3. Thomas DL. 2013. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19:850-858. http://dx.doi.org/10.1038/nm.3184.
4. Drenth JP. 2013. HCV treatment-no more room for interferonologists? N. Engl. J. Med. 368:1931-1932. http://dx.doi.org/10.1056/NEJMe1303818.
5. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitisCinfection. N. Engl. J. Med. 361:580-593. http://dx.doi.org/10.1056/NEJMoa0808010.
6. Kau A, Vermehren J, Sarrazin C. 2008. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 49:634-651. http://dx.doi.org/10.1016/j.jhep.2008.07.013.
7. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, Vidaud M, Marcellin P. 2009. Gene expression and hepatitis C virus infection. Gut 58:846-858. http://dx.doi.org/10.1136/gut.2008.166348.
8. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. 2005. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437-1444. http://dx.doi.org/10.1053/j.gastro.2005.01.059.
9. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46:1548-1563. http: //dx.doi.org/10.1002/hep.21853.
10. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. 2008. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 105:7034-7039 http://dx.doi.org/10.1073/pnas.0707882105.
11. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S, Hokuriku Liver Study Group. 2010. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139:499-509. http://dx.doi.org/10.1053/j.gastro.2010.04.049.
12. Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, Murakami Y. 2011. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One 6:e19799. http://dx.doi.org/10.1371/journal.pone.0019799.
13. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH. 2007. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J. Virol. 81:3391-3401. http://dx.doi.org/10.1128/JVI.02640-06.
14. Estrabaud E, Vidaud M, Marcellin P, Asselah T. 2012. Genomics and HCVinfection: progression of fibrosis and treatment response. J. Hepatol. 57:1110-1125. http://dx.doi.org/10.1016/j.jhep.2012.05.016.
15. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K. DITTO-HCV Study Group. 2011. Response prediction in chronic hepatitis C by assess-ment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6:e17232. http://dx.doi.org/10.1371/journal.pone.0017232.
16. Claassen MA, de Knegt RJ, Janssen HL, Boonstra A. 2011. Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapyinduced hepatitis C virus eradication in humans. J. Virol. 85:5323-5330. http://dx.doi.org/10.1128/JVI.02551-10.
17. Claassen MA, de Knegt RJ, Turgut D, Groothuismink ZM, Janssen HL, Boonstra A. 2012. Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferonalpha/ ribavirin therapy. PLoS One 7:e49389. http://dx.doi.org/10.1371 /journal.pone.0049389.
18. Wu Z, Irizarry R, Gentleman R, Martinez Murillo F, Spencer F. 2004 A model based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99:909. http://dx.doi.org/10.1198 /016214504000000683.
19. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445. http://dx.doi.org /10.1073/pnas.1530509100.
20. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98:5116-5121. http://dx.doi.org/10.1073/pnas.091062498.
21. Taylor J, Tibshirani R, Efron B. 2005. The ' miss rate' for the analysis of gene expression data. Biostatistics 6:111-117. http://dx.doi.org/10.1093 /biostatistics/kxh021.
22. Pham TN, Lin DM, Mulrooney-Cousins PM, Churchill ND, Kowala-Piaskowska A, Mozer-Lisewska I, Machaj A, Pazgan-Simon M, Zalewska M, Simon K, King D, Reddy SB, Michalak TI. 2013. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment. J. Med. Virol. 85:441-448. http://dx.doi.org/10.1002/jmv.23481.
23. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. 2010. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 91:382-388. http://dx.doi.org/10.1099/vir.0.015388-0.
24. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V. 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-164. http://dx.doi.org/10.1016/j.immuni.2008.05.012.
25. Medrano J, Barreiro P, Resino S, Tuma P, Rodriguez V, Vispo E, Labarga P, Madejon A, Garcia-Samaniego J, Jimenez-Nacher I, Martin-Carbonero L, Soriano V. 2009. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin. Infect. Dis. 49:1397-1401 http://dx.doi.org/10.1086/630205.
26. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. 2012 Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J. Viral Hepat. 19:e97-e104. http://dx.doi.org/10.1111/j.1365-2893.2011.01512.x.
27. Bolen CR, Robek MD, Brodsky L, Schulz V, Lim JK, Taylor MW, Kleinstein SH. 2013. The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J. Interferon Cytokine Res. 33:15-23. http://dx.doi.org/10.1089 /jir.2012.0037.
28. Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H. 2011. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53: 1819-1829. http://dx.doi.org/10.1002/hep.24285.
29. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F. 2001. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20:1509-1518. http://dx.doi.org/10.1038/sj.onc.1204175.
30. Xu B, Di J, Wang Z, Han X, Li Z, Luo X, Zheng Q. 2013. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. Biochem. Biophys. Res. Commun. 438: 324-328. http://dx.doi.org/10.1016/j.bbrc.2013.07.070.
31. Zhang X, Li HM, Liu Z, Zhou G, Zhang Q, Zhang T, Zhang J, Zhang C. 2013. Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J. Gastroenterol. 48:132-143. http://dx.doi.org/10.1007/s00535-012-0621-0.
32. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. 2012. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 56:994-1003. http://dx.doi.org/10.1002 /hep.25706.